课题基金 / 基金详情

The roles of the core autophagy protein ATG4B in chronic myeloid leukemia acquired drug resistance and its therapeutic implications

The roles of the core autophagy protein ATG4B in chronic myeloid leukemia acquired drug resistance and its therapeutic implications
核心自噬蛋白ATG4B在慢性粒细胞白血病获得性耐药中的作用及其治疗意义
批准号：
365540
负责人：
Porter Vanessa L
金额：
$7.65万
依托单位：
BC Cancer, part of PHSA (Vancouver)
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-10-01 至 2019-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=365540&lang=en
关键词：
Autophagy Cancer Stem Cells Cell Culture Chronic Myeloid Leukemia Drug Resistance Epigenetics Microrna Mouse Models Oncogenes Treatment Strategies

项目摘要

项目成果

Porter Vanessa L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Current treatment for chronic myeloid leukemia (CML) relies on inhibitors such as Imatinib Mesylate (IM) and newer iteration tyrosine kinase inhibitors (TKIs) to target the fusion protein, BCR-ABL1, which characterizes CML as a disease. However, BCR-ABL1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting autophagy in chronic myeloid leukemia through inhibition of the core autophagy protein ATG4B
海外基金